How to take methylene blue: what do the sources say?
| Product | Strength | Label direction |
|---|---|---|
| Provayblue injection1 | 10 mg/2 mL and 50 mg/10 mL, both 5 mg/mL | 1 mg/kg intravenously over 5-30 minutes |
| Ozipco solution, sold as a dietary supplement6 | 1%, 59.2 ml bottle | Mix 1 ml (20 drops) with 200 ml of water, or use according to established research protocols; for adult use only |
| Uro-MP, combination product2 | 10 mg per unit | Adults: one tablet orally 4 times per day followed by liberal fluid intake |
| Uribel, combination product3 | 10.8 mg per tablet | Adults: one tablet orally 4 times per day followed by liberal fluid intake |
Forms and strengths on the labels
The table is set at the top of the page
The pack's DailyMed search found only these four labels, and no label giving strengths of oral methylene blue supplement capsules.623
Route, approval and warnings
The Provayblue label indicates the injection for pediatric and adult patients with acquired methemoglobinemia, gives the dose intravenously and says not to give it subcutaneously.1 The label gives an initial U.S. approval of 2016 for the injection, and the TGA says methylene blue products are only prescription-only when presented for injection.17 It carries a boxed warning on serotonin syndrome with serotonergic drugs and opioids, and it contraindicates use in G6PD deficiency.1 Australia's TGA says unregistered oral methylene blue products in Australia have not been assessed for quality, safety or efficacy, advises against using them unless advised or prescribed by a healthcare professional, and names serious risks including serotonin syndrome, birth defects and haemolysis.7
Doses on the label and in trials
The Provayblue label allows a repeat of up to 1 mg/kg one hour later if methemoglobin stays above 30% or symptoms persist.1 The label puts the maximum number of doses at two, and gives a single dose of 1 mg/kg in moderate or severe renal impairment (eGFR 15-59 mL/min/1.73 m2).1 The pack's PubMed and ClinicalTrials.gov searches found no human trial of repeated oral low-dose methylene blue for wellness; the methylene blue trials below gave single doses.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Walter-Sack et al., 2009, phase I5 | 500 mg oral aqueous and 50 mg intravenous; then chloroquine 750 mg oral alone or with 500 mg oral | 16 healthy people | Single doses, 1-week wash-out, then a second week |
| Repici et al., 2012, MMX tablets8 | 200 mg or 400 mg oral; 200 mg also compared with 100 mg intravenous, after 2 L of bowel cleansing preparation | 22 healthy volunteers | Single dose |
| Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX (NCT03287219), open-label registry record, started 20114 | Six or eight 25 mg MMX tablets (150 or 200 mg), oral, with a 4-L PEG-based bowel cleansing preparation | 114 patients undergoing a full colonoscopy | Single dose |
| Rodriguez et al., 20169 | Low-dose oral methylene blue or placebo | Twenty-six subjects aged 22–62 years | Imaging before and 1 hour after dosing |
| Wilcock et al., LMTM trial10 | 100 mg or 4 mg twice a day, oral tablets | 800 people with mild Alzheimer's | Up to 78 weeks |
| LUCIDITY, Wischik et al.11 | Hydromethylthionine mesylate 16 mg/day, 8 mg/day or placebo, 4:1:4 | 545 patients with probable AD or MCI-AD | Double-blind phase, then open-label 16 mg/day |
The last two rows test LMTM, which its authors say stabilizes the reduced form of the MT moiety in the solid state,10 and hydromethylthionine mesylate,11 forms that differ from methylene blue chloride and whose doses are not interchangeable with it. The authors of the LMTM paper note an earlier phase 2 trial in which methylthioninium chloride at 138 mg/day produced a significant treatment effect on the ADAS-cog at 24 weeks compared with placebo.10 The pack's searches found no brain health, performance or cycling label or trial. Milligram has no logged methylene blue figure to report.
Mixing, dilution and storage
The Provayblue label says the injection may be diluted in 50 mL of 5% Dextrose Injection to avoid local pain, particularly in the pediatric population, and the diluted solution used immediately.1 The pack's searches found no label or trial naming a water or volume for an oral powder, and none gives a U-100 syringe mark.
The Provayblue label gives storage at 20°C to 25°C with excursions to 15°C to 30°C, no refrigeration or freezing, and the original package to protect from light.1 The pack's searches found no stability data for home-mixed solutions.
Frequently asked questions
How much of an oral dose of methylene blue is absorbed?
In Walter-Sack et al.'s 2009 phase I study of 16 healthy people, absolute bioavailability of a single 500 mg aqueous oral dose was 72.3 +/- 23.9%.5 In Repici et al.'s 2012 study of 22 healthy volunteers, 200 mg MMX tablets taken after 2 L of bowel cleansing preparation peaked at a median of 16 h, with average absolute bioavailability of 139.19 ± 52.00% against 100 mg intravenous.8 The two figures come from an aqueous oral dose and from MMX tablets taken with a bowel cleansing preparation.
References
- American Regent (DailyMed). These highlights do not include all the information needed to use (PROVAYBLUE) safely and effectively. See full prescribing information for (PROVAYBLUE). PROVAYBLUE ® (methylene blue) injection, USP for intravenous use Initial U.S. Approval: 2016. 2025. dailymed.nlm.nih.gov
- DailyMed. URO-MP Capsules. 2025. dailymed.nlm.nih.gov
- DailyMed. Uribel Tabs. 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov. NCT03287219: Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX. 2021. clinicaltrials.gov
- PubMed. High absolute bioavailability of methylene blue given as an aqueous oral formulation. 2009. pubmed.ncbi.nlm.nih.gov
- DailyMed. DIRECTIONS. 2026. dailymed.nlm.nih.gov
- Therapeutic Goods Administration (Australia). Imported unregistered methylene blue products. tga.gov.au
- PubMed. Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. 2012. pubmed.ncbi.nlm.nih.gov
- PMC. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. pmc.ncbi.nlm.nih.gov
- PMC. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. 2017. pmc.ncbi.nlm.nih.gov
- PMC. Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. 2022. pmc.ncbi.nlm.nih.gov